Yet another therapy with FDA accelerated approval suffers a setback; Sage’s tough year continues; Sanofi drops $326 million ...

EF Hutton has initiated coverage on ImmunityBio Inc. (NASDAQ:IBRX), a vertically integrated biotechnology company developing ...

Bladder cancer makes up about 4% of cancers, most commonly affecting people 55 and older. While rates for bladder cancer are ...

Gilead, manufacturer of the TROP2-directed antibody-drug conjugate sacituzumab govitecan, made the decision to withdraw the ...

If prostate cancer spreads to other parts of the body, it can become deadly and commonly moves to bones, the lungs, lymph ...

Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients ...

Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...

Matthew R. Zibelman, MD, discusses differing opinions in muscle-invasive bladder cancer treatment he heard when moderating a Case-Based Roundtable event.

A personalized strategy of dose-escalated radiotherapy (RT) for bladder cancer had a low rate of severe late toxicity and ...

The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...

Researchers found that DNA mutations from antiviral enzymes and chemotherapy fuel early bladder cancer, while abnormal ...